Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Diagnosis And Prognosis-review Of Biomarkers For Mesothelioma.

H. H. Sun, Allen Vaynblat, H. Pass
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma (MPM) is an aggressive disease arising in pleural cell lining and is associated with asbestos exposure. Today, there is a rising incidence of MPM reaching 3,000 annual cases nationally, primarily from the large population occupationally exposed to asbestos between 1940 and 1980. With a prolonged latency period, presenting clinically 10 to 40 years after exposure, MPM is often diagnosed in late stages and presents median survival time of less than 12 months. There is a serious need for improvement in prognostic and diagnostic tools for MPM. Recent investigation and discovery of various biomarkers has shown promise, including Osteopontin, Fibulin-3, Soluble Mesothelin-Related Proteins (SMRP), High Mobility Group Box 1 (HMGB1), micro-RNA's, peripheral blood-based markers, and Slow Off-rate Modified Aptamer (SOMAmer) proteomic assays. In this review, we explore these current major biomarkers and their prognostic and diagnostic potential, highlighting the most recent large studies and developments for each. While progress has been made in mesothelioma research, many questions remain unanswered. Increased international cooperation is necessary for improving validity of results for current biomarkers through repeated investigation and increasing cohort sizes, as well as for the continued search for new and better markers.
This paper references
10.1309/AJCP0F6WYBXGVDHX
Tumor/stromal caveolin-1 expression patterns in pleural mesothelioma define a subgroup of the epithelial histotype with poorer prognosis.
L. Righi (2014)
10.1158/0008-5472.CAN-09-3993
hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.
H. Pass (2010)
10.1016/j.lungcan.2015.07.014
Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma.
T. Yamagishi (2015)
10.1371/journal.pone.0070940
Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM)
C. Wright (2013)
10.1007/s12094-013-1146-6
Expression of Wilms’ tumor gene (WT1) is associated with survival in malignant pleural mesothelioma
S. Cedrés (2013)
10.1007/s00408-016-9868-1
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure
Melike Demir (2016)
10.1007/s12032-014-0303-2
Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component
S. Matsumoto (2014)
10.5301/jbm.5000229
Serum Mesothelin, Osteopontin and Vimentin: Useful Markers for Clinical Monitoring of Malignant Pleural Mesothelioma
A. Bonotti (2017)
10.1158/1078-0432.CCR-15-1130
HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
A. Napolitano (2016)
10.1309/TWCQV536WWRNEU51
Prognostic role of osteopontin expression in malignant pleural mesothelioma.
S. Cappia (2008)
10.1515/CCLM.2010.066
Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels
A. Rai (2010)
10.1016/j.lungcan.2012.02.022
Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM).
S. Cedrés (2012)
10.1056/NEJMoa1115050
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
10.1016/j.exer.2009.09.018
Focus on molecules: fibulin-3 (EFEMP1).
Y. Zhang (2010)
10.1097/JTO.0b013e31823f45c1
Inflammation-Based Prognostic Indices in Malignant Pleural Mesothelioma
D. Pinato (2012)
10.1378/chest.11-0129
The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor.
Kevin Hollevoet (2012)
10.1097/JTO.0b013e31821e1c08
Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma
A. Cristaudo (2011)
10.1158/1078-0432.CCR-03-0801
Mesothelin: a new target for immunotherapy.
R. Hassan (2004)
10.1158/1078-0432.CCR-11-2259
Molecular Pathways: Targeting Mechanisms of Asbestos and Erionite Carcinogenesis in Mesothelioma
M. Carbone (2011)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.5301/JBM.2009.5043
Osteopontin is not a specific marker in malignant pleural mesothelioma.
L. Paleari (2009)
10.1097/JTO.0b013e31822a3740
Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy
S. Kao (2011)
10.1038/bjc.2015.286
Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
M. Kirschner (2015)
10.1177/172460081002500307
Comparison between Plasma and Serum Osteopontin Levels: Usefulness in Diagnosis of Epithelial Malignant Pleural Mesothelioma
A. Cristaudo (2010)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1016/j.jtho.2016.02.006
Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma
H. Pass (2016)
10.1136/thoraxjnl-2014-205205
Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
J. Creaney (2014)
10.1016/j.lungcan.2015.09.021
Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma.
L. Santarelli (2015)
10.1016/j.cca.2014.02.024
Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis.
Z. Hu (2014)
10.1097/MCG.0b013e318297fa65
Serum HMGB1 as a Diagnostic Marker for Malignant Peritoneal Mesothelioma
C. Tabata (2013)
Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
P. Ferro (2013)
10.2217/fon.15.271
FBLN-3 as a biomarker of pleural plaques in workers occupationally exposed to carcinogenic fibers: a pilot study.
V. Rapisarda (2015)
10.1146/annurev.med.59.053006.104707
MicroRNAs in Cancer.
R. Garzon (2009)
10.1159/000355687
Is Soluble Mesothelin-Related Protein an Upfront Predictive Marker of Pleural Mesothelioma? A Prospective Study on Italian Workers Exposed to Asbestos
R. Filiberti (2013)
10.1097/PAS.0000000000000176
p16 FISH Deletion in Surface Epithelial Mesothelial Proliferations Is Predictive of Underlying Invasive Mesothelioma
H. Hwang (2014)
10.2174/1871520611313020014
The role of mesothelin in tumor progression and targeted therapy.
Zhewei Tang (2013)
10.1007/s00420-013-0853-1
Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers
M. K. Felten (2013)
10.18632/oncotarget.12408
Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers
I. Bononi (2016)
10.1189/jlb.0306164
DAMPs, PAMPs and alarmins: all we need to know about danger
M. Bianchi (2007)
10.1002/path.4567
Epigenetic down‐regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma
V. László (2015)
10.1002/pmic.200800284
Proteomic differential display analysis identified upregulated astrocytic phosphoprotein PEA‐15 in human malignant pleural mesothelioma cell lines
Y. Kuramitsu (2009)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1016/j.ctrv.2011.01.001
Advances in the biology of malignant pleural mesothelioma.
P. Zucali (2011)
10.1097/PAT.0000000000000250
Loss of expression of BAP1 predicts longer survival in mesothelioma
M. Farzin (2015)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
10.7314/APJCP.2015.16.4.1403
Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma.
H. Kaya (2015)
10.1007/s00408-013-9526-9
Serum Biomarkers in Patients with Mesothelioma and Pleural Plaques and Healthy Subjects Exposed to Naturally Occurring Asbestos
Mehmet Bayram (2013)
10.1016/j.jmoldx.2014.03.002
Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma.
M. Andersen (2014)
10.1371/journal.pone.0046091
Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals with a Noninvasive Proteomics-Based Surveillance Tool
R. Ostroff (2012)
10.1016/j.canlet.2012.06.019
The dual role of fibulins in tumorigenesis.
Álvaro J. Obaya (2012)
10.1158/1078-0432.CCR-07-0629
Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer
A. Cristaudo (2007)
10.1097/JTO.0b013e318187491c
Diagnostic and Prognostic Value of Soluble Mesothelin-Related Proteins in Patients with Malignant Pleural Mesothelioma in Comparison with Benign Asbestosis and Lung Cancer
J. Schneider (2008)
10.1097/JTO.0b013e3182272294
Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma
K. Hollevoet (2011)
10.1007/s12032-012-0422-6
Individual predictors of increased serum mesothelin in asbestos-exposed workers
R. Filiberti (2013)
10.1155/2013/874212
Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
J. Creaney (2013)
10.1093/CARCIN/21.5.1023
mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats.
H. Sandhu (2000)
10.1371/journal.pone.0026332
From SOMAmer-Based Biomarker Discovery to Diagnostic and Clinical Applications: A SOMAmer-Based, Streamlined Multiplex Proteomic Assay
S. Krämer (2011)
10.3892/IJO.25.1.173
Interleukin-1β and tumour necrosis factor-α promote the transformation of human immortalised mesothelial cells by erionite
Y. Wang (2004)
10.17877/DE290R-6925
Identification of circulating miRNAs profiles that distinguish malignant pleural mesothelioma from lung adenocarcinoma
LV Gayosso-Gómez (2014)
10.1038/modpathol.2015.65
BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations
Marta Cigognetti (2015)
10.1016/j.molonc.2014.11.007
MiR‐Score: A novel 6‐microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma
M. Kirschner (2015)
10.1016/j.cllc.2012.03.011
Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
S. Kao (2013)
10.1097/PAS.0000000000000616
BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas
H. Hwang (2016)
10.1016/J.JSS.2004.03.028
The role of Osteopontin in tumor metastasis.
P. Wai (2004)
10.1186/1471-2407-14-674
A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice
M. Linch (2013)
10.1158/1078-0432.CCR-10-2245
High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy
S. Kao (2010)
10.1016/j.pathol.2016.08.003
Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma.
B. Thapa (2016)
10.1038/bjc.2013.504
Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma
T. Meniawy (2013)



This paper is referenced by
10.3389/fgene.2020.00975
Variation rs2235503 C > A Within the Promoter of MSLN Affects Transcriptional Rate of Mesothelin and Plasmatic Levels of the Soluble Mesothelin-Related Peptide
Roberto Silvestri (2020)
The influence of selected polymorphisms in matrix metalloproteinases on response to treatment and disease progression in patients with mesothelioma
Danijela Štrbac (2019)
10.3390/medicina55080490
Malignant Pleural Effusion and Its Current Management: A Review
Kristijan Skok (2019)
10.5772/intechopen.89438
Asbestos-Related Diseases and Blood Biomarkers
A. Franko (2019)
10.1155/2019/1242964
Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma
Danijela Štrbac (2019)
10.3389/fonc.2020.01742
The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review
Eric Rozitis (2020)
Malignant pleural mesothelioma : recognising an unmet need
Samal Gunatilake (2018)
10.1007/978-3-030-16884-1_8
Tissue and Circulating Biomarkers in Mesothelioma
Paolo Andrea Zucali (2019)
10.21873/cgp.20183
Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome
Serena Lacerenza (2020)
10.1093/carcin/bgz103
Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Christina Gillezeau (2019)
10.1093/ejcts/ezaa158
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
I. Opitz (2020)
10.1016/j.lungcan.2019.11.013
Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
P. Stockhammer (2019)
10.1155/2017/2536187
SFRP Tumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma
Y. Cheng (2017)
10.1002/jcp.29414
Data mining analysis of the PP2A cell cycle axis in mesothelioma patients
R. Pippa (2019)
10.1183/13993003.00953-2019
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
A. Scherpereel (2020)
10.3390/ijms19051297
In Silico and In Vitro Analyses of LncRNAs as Potential Regulators in the Transition from the Epithelioid to Sarcomatoid Histotype of Malignant Pleural Mesothelioma (MPM)
A. S. Singh (2018)
10.1016/j.ebiom.2020.103031
A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma
Bill T V Duong (2020)
10.3892/ol.2018.8117
Expression of the microRNA-143/145 cluster is decreased in hepatitis B virus-associated hepatocellular carcinoma and may serve as a biomarker for tumorigenesis in patients with chronic hepatitis B
Q. Zhao (2018)
10.3892/ol.2018.9323
Identification of potential biomarkers in cervical cancer with combined public mRNA and miRNA expression microarray data analysis
Sizhe Wang (2018)
Risk factors and biomarkers for malignant mesothelioma
Vasiliki Panou (2019)
10.21037/tlcr.2018.04.09
Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review.
Lisa Brusselmans (2018)
10.2147/OTT.S145105
Amatuximab and novel agents targeting mesothelin for solid tumors
P. Baldo (2017)
10.21873/anticanres.13719
Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma
V. Fontana (2019)
10.1186/s12943-018-0891-0
Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis
Patrick Smeele (2018)
10.1016/j.thorsurg.2020.08.005
The Molecular Basis of Malignant Pleural Mesothelioma.
Benjamin Wadowski (2020)
Semantic Scholar Logo Some data provided by SemanticScholar